C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Increasing the efficiency of bioprocess workflows is key to stay competitive. The SciVario twin helps to develop and optimize processes in terms of time and cost efficiency. All critical process parameters can be precisely controlled directly at the controller’s touch screen. Regardless of the research segment, it is suitable for microbial and cell culture applications. The innovative bay-drawer system enables the system to flexibly adapt to unique requirements and changing processes. Eppendorf will offer updates with new functional modules, support for more, larger bioreactors, and additional software features to make the SciVario twin a future-proof solution.
Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
The regulatory situation regarding the trade of medicinal cannabis currently varies enormously from country to country within the European Union. Unfortunately, there is still no full regulatory harmonization on a European level.
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus’ main protease.
Researchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells